highly effective and safe primary treatment modality. Initial thrombosis rates exceeded 90% and no serious complications were observed in this series despite a high rate of concomitant antiplatelet and antithrombotic therapy. 
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Transradial approach decreases in-hospital mortality in patients with cardiogenic shock. A single-center experience 
HU Germans Trias i Pujol, Badalona, Spain
Background: Transradial approach (TRA) in percutaneous coronary intervention (PCI) has increased over the past few years. Its use has been shown to decrease mortality compared with the transfemoral approach (TFA) in patients with acute coronary syndrome (ACS). Comparative studies have systematically excluded patients with cardiogenic shock (CS). Methods: We carried out a prospective, observational registry study of consecutive patients undergoing emergent revascularization between February 2007 and January 2012. An analysis of the clinical evolution of patients with CS during hospitalization was performed according to the approach used in the PCI. Results: Of 1,400 emergency procedures, 122 had CS, 80 underwent PCI by TRA (65.6%) and 42 by TFA (34.3%). The main reason for choosing TFA was the absence of radial pulse (54.9%). Mortality (64.3% vs. 32.5%, pϭ0.001), serious access site complications (11.9% vs. 2.5%, pϭ0.03) and MACE (combination of death, infarction, stroke, serious bleeding, and postanoxemic encephalopathy) (73.8% vs. 43.8%, pϭ0.001) were greater in TFA patients. In the multivariate analysis, TRA was a predictor of mortality ); other predictive factors were ageՆ75 (3.47[1.35-8.92] ), previous treatment with diuretics (3.67[1.21-11.12] ) and the success of the procedure (0.08[0.02-0.24]). Conclusions: In centers with experience, TRA approach for PCI is possible and safe in patients with CS in up to two thirds of the patients. The main cause that prevented the use of TRA was the absence of radial pulse. In the multivariate analysis, TRA was associated with a lower risk of mortality. Background: Ballooon aortic valvulplasty can be useful for palliation of symptoms in pts not eligible for surgical or transcatheter aortic vaalve replacement, or a a bridge to AVR. Occassionally transfemoral access is impossible or challenging, due to vascular disease or morbid obesity. We present our experience with trasnradial access for balloon aortic valvulplasty in pts not candidates for transfemoral approach. Methods: 5 pts presented with critical aortic stenosis without femoral access. Transradial access was successfully obtained in all pts. In 1 pt a vascular loop prompted a change from the right to the left radial approach -the others were done via right radial access. Internal jugular venous access was used for PA catheter and pacing. After crossing the aortic valve using 6Fr amplatz 1 catheter with straight wire, and changing out for a dual lumen pigtail. Over an exchange length wire, the 6 Fr sheath was excheanged for an 8 Fr, and a 22 mm Tyshack balloon was advanced across the aortic valve and dilated during rapid pacing. Due to inadequate hemodynamics, in 1 case the 8 Fr sheath was exchanged for a 9 Fr, and a 25 mm Tyshack balloon used. Results: In 4 of 5 pts aortic valvuloplasty was attempted and successfully performed. In 1 pt with morbid orbesity vigourous diuresis was instead successful in treating his CHF and one year later he underwent successful surgical AVR. 1 of the pts with successful balloon valvuplasty had occlusive lower extremity arterial disease and need for warfarin for a mechanical mitral valve, the others had morbid obesity (mean weight 168 kg). All pts had hemodynamic improvement, mean AV gradient decreased from 47 to 36 (23%), and AVA increased from 0.85 to 1.1 (29% increase). The pt with 9 Fr sheath had small amount of tissue removed with removal of the 9 Fr sheath, but no clinical complications in any pt. Conclusions: Radial artery access is a feasible option for the performance of balloon aortic valvuloplasty in patients with poor femoral artery access. 
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Trans-radial balloon aortic valvuloplasty
TCT-407 Vascular Hemostasis Devices: Food And Drug Administration Perspective On Reported Risks
Roberta Sullivan
Results:
The FDA registration and listing database identified 8 different manufacturers and 11 different devices. FDA approval of the 11 devices occurred from 1995 through 2011. 10 of the 11 listed devices are made in the US by US manufacturers. Two manufacturers represented 95% of the VHDs reported in adverse events. The number of annual adverse events reports increased 300% from 1,402 in 2007 to 4,243 in 2011, with a five year total of 14,120 reports received. Geographically, 72% of the adverse events occurred in the US and 27% in 53 other countries. Females were disproportionately represented (pϽ 0.001, 44% vs. 34% expected). Patient age ranged from 4 to 98 years, with women found to be older than men (65.8 vs. 64.7, pϽ0.01) . A total of 164 reports for death as the patient outcome were received. For women, deaths were present in 3.38% of the reports compared to 1.28% for men (pϽ0.001, odds ratio 2.7 [CI 1.908, 3.802] ). During the timeframe there was one US recall for a compromised sterility issue and one foreign recall for increased failure rates. US Manufacturer and contractor inspections included four cases of FDA citations requiring actions. Conclusions: Reasons women experience higher risks are not known but appear to persist despite product experience and design changes. More research on gender differences and device design is recommended. Increased overall numbers of VHD adverse event reports to FDA likely parallels temporal increases in use. Limitations relate to missing data for patient age and gender, and known underreporting of adverse events. Background: The Sheathless Guiding Catheter (SGC) (Sheathless Eaucath, Asahi Intecc Co, Japan) has Hydrophilic coatings that enhances catheter tractability through tortuous vessels and allow dealing with radial spasm and performing Percutaneous Coronary Intervention (PCI) by radial approach in complex cases. We reported our experience in 91 patients (pts) with complex transradial approach in whom SGC was used to avoid femoral cross over to complete the procedure. 
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